89bio to Participate in Upcoming Investor Conferences
May 03, 2022 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, May 03, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Host Key Opinion Leader Webinar on Severe Hypertriglyceridemia (SHTG)
April 26, 2022 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, April 26, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 24, 2022 16:05 ET
|
89bio, Inc.
– Reported positive topline results from cohort 7 in the Phase 1b/2a trial including data from new analyses demonstrating the promising therapeutic utility of pegozafermin for the treatment of NASH – ...
89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors
February 24, 2022 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Participate in the SVB Leerink 11ᵗʰ Annual Global Healthcare Conference
February 09, 2022 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Positive Topline Results from an Expansion Cohort of the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH
January 24, 2022 16:05 ET
|
89bio, Inc.
63% of patients achieved 2-point or greater improvement in NAS without worsening of fibrosis; clinically meaningful improvements on registration enabling endpoints of NASH resolution (32%) and...
89bio Presents New Data from Phase 1b/2a NASH Study Showing BIO89-100 Reduces Spleen Volume
November 14, 2021 18:30 ET
|
89bio, Inc.
New sub-analysis presented at The Liver Meeting® 2021 shows treatment with BIO89-100 reduced spleen volume by an average of 11.8% in NASH patients Oral presentation was highlighted by the AASLD...
89bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 11, 2021 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Announces Appointment of Kathy LaPorte to its Board of Directors
November 03, 2021 08:00 ET
|
89bio, Inc.
SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021
October 25, 2021 16:05 ET
|
89bio, Inc.
SAN FRANCISCO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...